1. Home
  2. PFSA vs SCNI Comparison

PFSA vs SCNI Comparison

Compare PFSA & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PFSA

Profusa Inc.

HOLD

Current Price

$0.37

Market Cap

2.0M

Sector

Health Care

ML Signal

HOLD

SCNI

Scinai Immunotherapeutics Ltd.

HOLD

Current Price

$0.46

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFSA
SCNI
Founded
2009
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
2.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PFSA
SCNI
Price
$0.37
$0.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
437.6K
7.3M
Earning Date
04-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.44
52 Week High
$4.22
$6.18

Technical Indicators

Market Signals
Indicator
PFSA
SCNI
Relative Strength Index (RSI) 36.11 39.85
Support Level $0.28 $0.45
Resistance Level $0.41 $0.94
Average True Range (ATR) 0.04 0.06
MACD 0.00 -0.01
Stochastic Oscillator 9.25 10.79

Price Performance

Historical Comparison
PFSA
SCNI

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.

Share on Social Networks: